Go to content


Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 14 jan 2008 - 09:35
Statutaire naam MDxHealth
Titel OncoMethylome Sciences S.A. Licenses Several Key Technologies from Epigenomics AG
Bericht Liege (Belgium) and Berlin (Germany) – January 14, 2008, 8:00 CET – OncoMethylome Sciences S.A. (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) and Epigenomics AG (Frankfurt, Prime Standard: ECX) today announced that they have entered into a broad technology licensing agreement. Under the terms of the agreement, OncoMethylome obtained worldwide non-exclusive rights to several of Epigenomics’ proprietary core technologies such as its MethyLight portfolio for the sensitive and quantitative detection of DNA methylation for in vitro diagnostic product development and commercialization. Further, OncoMethylome obtained rights to HeavyMethyl® technology, plus certain microarray-based technologies for DNA methylation analysis. In return for the licenses, Epigenomics will receive an up-front payment and is eligible for royalties to be paid on any eventual commercial exploitation of the technologies by OncoMethylome and any of its partners who choose to sublicense such technology. Both companies continue to independently develop their own products and biomarker licenses have not been granted.

Datum laatste update: 22 april 2024